Events

Struggling to improve titre, product quality, or long-term stability in GS-CHO expression systems? In this free webinar, learn how optimized vector design — including advanced promoter engineering — can significantly impact biomanufacturing performance. The session highlights the Lonza GSquad® Pro platform and its high-performance LHP-1 promoter, along with data-driven strategies to improve gene expression control...

Selecting the right route of administration for a complex, large molecule biologic requires careful alignment of formulation, dose, and device strategy. Join Drug Delivery Leader's next live discussion where experts from Merck, GSK, and Drug Hunter Consulting will share key considerations—including formulation complexity, high-dose delivery, patient needs, self-administration, and transitioning between delivery platforms—using examples from...

Particulates and raw material variability remain two of the toughest, most talked about hurdles in cell and gene therapy. In the upcoming Cell & Gene Live, Anthony Blaszczyk, Ph.D., Senior Scientist at the U.S. Pharmacopeia, and Basak Clements, Ph.D., Founder and Senior Advisor at biomatria, join Cell & Gene Chief Editor Erin Harris to examine...

We are very excited to invite you to our indoor BVS Waltham/Winter Street Biotech Community Expo! Mark your calendars for a great opportunity to connect with industry leaders, explore innovative products, and mingle with fellow professionals in the biotech community. We are inviting all research scientists from the institutes, biotech/pharma and other companies along Winter...

Join this free webinar to see how Samsung Biologics integrates in-house vector construction and Master Cell Bank (MCB) manufacturing to streamline the VC-to-IND journey to approximately 9 months. You’ll learn how tighter alignment between vector design and cell banking: - Reduces handoffs and accelerates decision-making - Improves data continuity and risk management - Enhances predictability...

Regulators are moving the comparability goalpost, shifting the burden of proof from massive clinical trials to deep process understanding. In this new landscape, the ability to define and control CPPs is the only way to ensure a biosimilar remains highly similar to its reference. Join Bioprocess Online’s Jon O’Connell for a virtual Q&A with experts...

Explore how KBI Biopharma delivers fast, cost-effective, and robust microbial protein process development, tailored for first-in-human (FIH, Phase I) programs and adaptable to each client’s needs for speed, cost, and performance. Learning Objectives: - Key considerations for microbial cell line, fermentation, and purification development for FIH - How milestones align from proof-of-concept to toxicology material...